How to buy CRISPR Therapeutics (CRSP) shares in Australia

Learn how to easily invest in CRISPR Therapeutics shares.

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!

CRISPR Therapeutics AG is a biotechnology business with stocks listed in the US. CRISPR Therapeutics shares (CRSP) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$58.76 – a decrease of 6.15% over the previous week. Here's how to invest if you're based in Australia.

How to buy shares in CRISPR Therapeutics

  1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for CRISPR Therapeutics. Find the share by name or ticker symbol: CRSP. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until CRISPR Therapeutics reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of US$66.4, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of CRISPR Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of CRISPR Therapeutics. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

CRISPR Therapeutics stock price (NASDAQ:CRSP)

Use our graph to track the performance of CRSP stocks over time.

CRISPR Therapeutics shares at a glance

Information last updated 2022-01-23.
52-week rangeUS$62.21 - US$191.1
50-day moving average US$76.3982
200-day moving average US$108.2373
Target priceUS$149.11
PE ratio 11.8963
Dividend yield N/A (0%)
Earnings per share (TTM) US$5.263

Where to buy CRISPR Therapeutics stock

Name Product Standard brokerage for US shares Currency conversion fee Markets
eToro (global stocks)
US$0
50 pips (US$0.50 for every AU$100 exchanged)
Global shares, US shares, ETFs
Zero brokerage share trading on US, Hong Kong and European stocks with trades as low as $50.
Note: This broker offers CFDs which are volatile investment products and most clients lose money trading CFDs with this provider.
Join the world’s biggest social trading network when you trade stocks, commodities and currencies from the one account.
IG Share Trading
US$0
0.70%
ASX shares, Global shares
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.
Superhero share trading
US$0
50 pips (US$0.50 for every AU$100 exchanged)
ASX shares, US shares, ETFs
Earn up to 15,000 Qantas frequent flyer points when you transfer an exisiting balance or trade. Offer valid for all new and existing Superhero members until 28 February.
Pay zero brokerage on US stocks and all ETFs and just $5 (flat fee) to trade Australian shares from your mobile or desktop.
Saxo Capital Markets (Classic account)
US$4
1%
ASX shares, Global shares, ETFs
Access 19,000+ stocks on 40+ exchanges worldwide
Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.
SelfWealth (Basic account)
US$9.5
0.60%
ASX shares, US shares
Trade ASX and US shares for a flat fee of $9.50, regardless of the trade size.
New customers receive free access to Community Insights with SelfWealth Premium for the first 90 days. Follow other investors and benchmark your portfolio performance.
loading

Compare up to 4 providers

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy CRISPR Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

CRISPR Therapeutics share growth calculator

US$

Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.

CRISPR Therapeutics price performance over time

Historical closes compared with the last close of $58.76

1 month (2021-12-27) -23.65%
3 months (2021-10-28) -37.49%
6 months (2021-07-28) -50.93%
1 year (2021-01-28) -64.90%
2 years (2020-01-28) 6.18%
3 years (2019-01-28) 88.51%
5 years (2017-01-27) 218.83%

Is CRISPR Therapeutics under- or over-valued?

Valuing CRISPR Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of CRISPR Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

CRISPR Therapeutics's P/E ratio

CRISPR Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 12x. In other words, CRISPR Therapeutics shares trade at around 12x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

CRISPR Therapeutics's EBITDA

CRISPR Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$425.7 million (£318 million).

The EBITDA is a measure of a CRISPR Therapeutics's overall financial performance and is widely used to measure a its profitability.

CRISPR Therapeutics financials

Revenue TTM US$902.4 million
Operating margin TTM 45.6%
Gross profit TTM US$-266,227,000
Return on assets TTM 11.94%
Return on equity TTM 21.36%
Profit margin 45.64%
Book value 32.864
Market capitalisation US$4.8 billion

TTM: trailing 12 months

CRISPR Therapeutics share dividends

We're not expecting CRISPR Therapeutics to pay a dividend over the next 12 months.

Have CRISPR Therapeutics's shares ever split?

CRISPR Therapeutics's shares were split on a 333333:100 basis on 18 July 2016. So if you had owned 100 shares the day before the split, the next day you would own 333333 shares. This wouldn't directly have changed the overall worth of your CRISPR Therapeutics shares – just the quantity. However, indirectly, the new 100% lower share price could have impacted the market appetite for CRISPR Therapeutics shares which in turn could have impacted CRISPR Therapeutics's share price.

CRISPR Therapeutics share price volatility

Over the last 12 months, CRISPR Therapeutics's shares have ranged in value from as little as US$62.21 up to US$191.1. A popular way to gauge a stock's volatility is its "beta".

CRSP.US volatility(beta: 2.05)Avg. volatility(beta: 1.00)LowHigh

Beta measures a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while CRISPR Therapeutics's is 2.0471. This would suggest that CRISPR Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

CRISPR Therapeutics overview

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies; allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. It develops regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, myotonic dystrophy type 1, and cystic fibrosis. The company has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. The company was formerly known as Inception Genomics AG and changed its name to CRISPR Therapeutics AG in April 2014. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site